source
- Neoadjuvant T-DXd then THP cuts residual cancer burden vs standard chemo in high-risk HER2-positive breast cancerThe DESTINY‑Breast11 trial compared three neoadjuvant approaches for patients with high‑risk HER2‑positive early‑stage breast cancer: T‑DxD followed by paclitaxel, trastuzumab and pertuzumab (THP),…
- New SGO 2026 data show frontline checkpoint inhibitors give 4-year survival boost and almost no relapses after two years in dMMR cancersData presented at the 2026 Society of Gynecologic Oncology meeting highlight the performance of frontline checkpoint inhibitor regimens in patients with deficient mismatch repair (dMMR) cancers. T…onclive · 4mo agoPositive readoutPositive